Literature DB >> 16112814

Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls.

Katja Held1, Irina Antonijevic, Harald Murck, Heike Kuenzel, Axel Steiger.   

Abstract

Preclinical and clinical studies suggest that neuropeptide Y (NPY) exerts functional corticotropin-releasing hormone (CRH) antagonistic effects. NPY activity appears to be blunted in depression. Recently, we have found in young normal male controls after repetitive administration of NPY a shortened sleep latency and a decrease of time awake and, in the second half of the night, EEG delta-power; cortisol and ACTH levels were blunted. Since during depression there is an overactivity of CRH, we tested the capacity of NPY to affect sleep endocrine activity in patients with depression compared with controls. After one night of adaptation we administered hourly IV injections of placebo (PL) during the second night and of 50 microg NPY during the third night between 22:00 and 01:00 h. Throughout the night ACTH, cortisol and prolactin levels were measured, simultaneously the sleep electroencephalogram (EEG) was recorded. Depressed patients as well as healthy controls exhibited significant shortening of sleep onset latency (SOL) (mean+/-SD; controls: 41.9+/-48.2 min PL vs 22.1+/-17.3 min NPY; patients: 31.8+/-19.8 min PL vs 24.7+/-20.1 min NPY; P<0.06) and REM latency (controls: 79.3+/-27.5 min PL vs 69.0+/-19.4 min NPY; patients: 79.8+/-45.5 min PL vs 52.4+/-51.2 min NPY; P<0.05). Both patients and controls showed a trend to an increase of prolactin during the night. In contrast to our recent observation in young normal subjects time awake, ACTH and cortisol remained unchanged in patients and controls in response to NPY. Whereas also an adaptation effect may contribute to the shortening of SOL, this change and the prolactin elevation are in line with a CRH antagonistic and GABA(A) agonistic/benzodiazepine-like effect of NPY. The lack of effects on time awake and HPA hormones may be explained by the higher CRH activity due to age and depression in the investigated samples in comparison to our recent study in young subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112814     DOI: 10.1016/j.psyneuen.2005.05.015

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  14 in total

1.  Plasma neuropeptide Y levels in Chinese patients with primary insomnia.

Authors:  Qiaoting Huang; Jiwu Liao; Yaping Liu; Huajun Liang; Ping Ma; Jiyang Pan
Journal:  Sleep Breath       Date:  2014-09-27       Impact factor: 2.816

Review 2.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

3.  Neuropeptide Y Regulates Sleep by Modulating Noradrenergic Signaling.

Authors:  Chanpreet Singh; Jason Rihel; David A Prober
Journal:  Curr Biol       Date:  2017-12-07       Impact factor: 10.834

Review 4.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 5.  The Neurobiology of Sleep and Wakefulness.

Authors:  Michael D Schwartz; Thomas S Kilduff
Journal:  Psychiatr Clin North Am       Date:  2015-08-28

6.  Multi-ethnic GWAS and meta-analysis of sleep quality identify MPP6 as a novel gene that functions in sleep center neurons.

Authors:  Samar Khoury; Qiao-Ping Wang; Marc Parisien; Pavel Gris; Andrey V Bortsov; Sarah D Linnstaedt; Samuel A McLean; Andrew S Tungate; Tamar Sofer; Jiwon Lee; Tin Louie; Susan Redline; Mari Anneli Kaunisto; Eija A Kalso; Hans Markus Munter; Andrea G Nackley; Gary D Slade; Shad B Smith; Dmitri V Zaykin; Roger B Fillingim; Richard Ohrbach; Joel D Greenspan; William Maixner; G Gregory Neely; Luda Diatchenko
Journal:  Sleep       Date:  2021-03-12       Impact factor: 5.849

Review 7.  Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?

Authors:  Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

8.  Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.

Authors:  Nicole M Enman; Esther L Sabban; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015-01-01

Review 9.  Metabolic signals in sleep regulation: recent insights.

Authors:  Charu Shukla; Radhika Basheer
Journal:  Nat Sci Sleep       Date:  2016-01-05

10.  Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men.

Authors:  Wessel M A van Leeuwen; Mikael Sallinen; Jussi Virkkala; Harri Lindholm; Ari Hirvonen; Christer Hublin; Tarja Porkka-Heiskanen; Mikko Härmä
Journal:  Sleep Biol Rhythms       Date:  2017-09-08       Impact factor: 1.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.